BioAtla (NASDAQ: BCAB) CEO receives 430,000-share RSU grant
Rhea-AI Filing Summary
SHORT JAY M PHD reported acquisition or exercise transactions in this Form 4 filing.
BioAtla, Inc. CEO and director Jay M. Short received a grant of 430,000 shares of Common Stock in the form of a time-based restricted stock unit award. The award was granted at no cash cost and is structured to vest over several years.
According to the vesting schedule, 25% of the RSU is scheduled to vest on March 11, 2027, with an additional 6.25% vesting on the last day of each May, August, November and February thereafter, subject to his continued service. Following this grant, Dr. Short directly holds 2,659,603 shares of Common Stock.
The filing also lists indirect holdings in BioAtla shares held by his spouse, various 2020 irrevocable gift trusts, Capia IP, LLC and Himalaya Parent LLC. For Himalaya Parent LLC, he and his spouse act as managers and collectively make investment decisions, while each disclaims beneficial ownership except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
FAQ
What did BioAtla (BCAB) disclose about CEO Jay Short’s latest equity grant?
How do the 430,000 BioAtla RSUs granted to the CEO vest over time?
How many BioAtla shares does CEO Jay Short hold directly after this Form 4?
What indirect BioAtla (BCAB) holdings related to Jay Short are reported in the filing?
What does the filing say about Jay Short’s interest in Himalaya Parent LLC’s BioAtla shares?